Editorial—BioPharm Reflects the Industry
Welcome to the inaugural issue of the new BioPharm International. We are pleased to unveil our new logo and redesign after collaborating for four months with award-winning designer Virginia Dickens of Vision Advertising. One of our redesign goals was for the magazine to reflect the same innovative, cutting-edge qualities that are characteristic of the evolving biopharm industry. Probably more important to you is how the new format will better accommodate the expression of your day-to-day challenges.
Welcome to the inaugural issue of the new BioPharm International. We are pleased to unveil our new logo and redesign after collaborating for four months with award-winning designer Virginia Dickens of Vision Advertising. One of our redesign goals was for the magazine to reflect the same innovative, cutting-edge qualities that are characteristic of the evolving biopharm industry. Probably more important to you is how the new format will better accommodate the expression of your day-to-day challenges.
Carol L. Fisher
We understand you must juggle the development of new technologies while streamlining operations. You create strategic alliances that require your adjustment to new business paradigms. You build cGMP-compliant plants and strive to meet FDA guidelines and requirements. You implement new business models to ensure rewarding career paths for your employees and long-term value for the shareholders. Then there's the science — the foundation of your professional existence and the primary focus of BioPharm International.
We've added new elements to make BioPharm the first "must-read" publication on your desk. Global News Network offers developments most likely to affect your professional efforts. You'll know how regions, states, and countries are preparing to become the next biotech hubs by reading Regional Round-Up and International BioMarket
Besides upgrading the magazine, we've made changes to our website (www.biopharm-mag.com), including a user-friendly home page that now hosts daily news.
The staff has evolved too. With the addition of Ivette Litt as art director, the transition of BioPharm headquarters from Eugene, OR to Iselin, NJ is complete. Ivette bravely accepted the task of introducing the redesign while also preparing the 21 CFR Part 11 supplement.
Michael McGregor recently joined the team as senior editor in charge of news, supplements, and primers. Previously, Michael worked with the Manisses Communications Group, Princeton Review, and Brown University. Peter Silverberg, associate editor, trained at MIT in chemical engineering and has extensive editorial experience plus a broad base of practical knowledge as a chemical and analytical engineer.
BioPharm appreciates your challenges, and we intend to support you with the most sophisticated tools, processes, and staff in the business.
Carol L. Fisher, Editor in Chief
BioPharm International
Mastering Antibody-Drug Conjugates: BIOVECTRA's Approach to ADC and Complex Chemistry Manufacturing
December 19th 2024BioPharm International sat down with Jean-François Vincent-Rocan, Director of Complex Chemistry Process Development at BIOVECTRA, to discuss antibody-drug conjugate (ADC) manufacturing. Due to their complex manufacture and supply chain management, JF emphasizes the need for a company that greatly understands the challenges and offers solutions that maintain quality and reliability. He also mentions what advancements are to come in this field and how best to stay ahead of a rapidly growing treatment option.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
